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Abstract
Background: Forty per cent of critically ill patients are affected by intensive care unit-acquired weakness (ICU-AW),
to which skeletal muscle wasting makes a substantial contribution. This can impair outcomes in hospital, and can
cause long-term physical disability after hospital discharge. No effective mitigating strategies have yet been identified.
Application of a repetitive vascular occlusion stimulus (RVOS) a limb pressure cuff inducing brief repeated cycles of
ischaemia and reperfusion, can limit disuse muscle atrophy in both healthy controls and bed-bound patients
recovering from knee surgery. We wish to determine whether RVOS might be effective in mitigating against muscle
wasting in the ICU. Given that RVOS can also improve vascular function in healthy controls, we also wish to assess such
effects in the critically ill. We here describe a pilot study to assess whether RVOS application is safe, tolerable, feasible
and acceptable for ICU patients.
Methods: This is a randomised interventional feasibility trial. Thirty-two ventilated adult ICU patients with multiorgan
failure will be recruited within 48 h of admission and randomised to either the intervention arm or the control arm.
Intervention participants will receive RVOS twice daily (except only once on day 1) for up to 10 days or until ICU
discharge.
Serious adverse events and tolerability (pain score) will be recorded; feasibility of trial procedures will be assessed
against pre-specified criteria and acceptability by semi-structured interview. Together with vascular function, muscle
mass and quality will be assessed using ultrasound and measures of physical function at baseline, on days 6 and 11
of study enrolment, and at ICU and hospital discharge. Blood and urine biomarkers of muscle metabolism, vascular
function, inflammation and DNA damage/repair mechanism will also be analysed. The Health questionnaire will be
completed 3months after hospital discharge.
Discussion: If this study demonstrates feasibility, the derived data will be used to inform the design (and sample size)
of an appropriately-powered prospective trial to clarify whether RVOS can help preserve muscle mass/improve vascular
function in critically ill patients.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: bencb@nhs.net
1Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust,
Guildford GU2 7XX, UK
2Faculty of Health and Medical Sciences, School of Biosciences and Medicine,
University of Surrey, Guildford, UK
Full list of author information is available at the end of the article
Chhetri et al. Trials          (2019) 20:456 
https://doi.org/10.1186/s13063-019-3547-5
(Continued from previous page)
Trial registration: ISRCTN Registry, ISRCTN44340629. Registered on 26 October 2017.
Keywords: Repetitive vascular occlusion stimulus, ICU-acquired weakness, Blood flow restriction, Critical illness,
Rehabilitation, Muscle atrophy, Vascular dysfunction
Background
Increasing numbers of patients are being admitted to
intensive care units (ICUs) and mortality rates have
fallen [1–3]. However, survival comes at the expense of
increased dependency and debility: 50% of patients of
working age do not return to work; 70% require assist-
ance with daily living activities in the year following dis-
charge; and physical disability can persist for many years
[4, 5]. The UK’s National Institute of Health and Care
Excellence (NICE) has declared such post-ICU debility
to be a public health issue [6].
Impaired quality of life and functional limitation partly
result from ICU-acquired weakness (ICU-AW) [7–10].
This affects approximately 40% of adult ICU patients [11],
with long-term ventilated or severely septic patients being
most commonly and severely affected [12–16]. ICU-AW is
associated with poorer outcomes: prolonged mechanical
ventilation, increased ICU and hospital length of stay, in-
creased hospital and post-discharge mortality rates, chronic
functional disability and reduced quality of life among sur-
vivors [8, 17–20]. As a consequence, hospital health-care
costs are 30% higher in those affected, with further excess
costs relating to the need for rehabilitation, frequent re-ad-
missions and social care upon discharge [18].
The pathophysiology of ICU-AW is multifactorial [10,
21–23]. Whilst neuropathies may occur [24], skeletal
muscle wasting plays a central role [25]. The cross-sectional
area of the rectus femoris (thigh) muscle (RFCSA) falls by
an average of 18% in just 10 days in ventilated ICU patients,
and to the greatest degree in those with the largest burden
of organ failure [21]. This is underpinned by impaired
skeletal muscle protein synthesis and, simultaneously,
increased protein breakdown [21, 26], to which altered
muscle metabolism [27] and disuse may contribute [23, 28].
The putative role of drugs such as corticosteroids, neuro-
muscular junction blocking agents and aminoglycoside
antibiotics is contested [16, 29–31].
To date, no therapies exist for prevention or treatment
of ICU-AW [32, 33]. Early mobilisation and physical acti-
vity regimes have proven ineffective [34–38], perhaps
because muscle wasting has already occurred. There is thus
growing interest in the early application of non-volitional
interventions such as neuromuscular electrical stimulation,
although proof of benefit remains lacking [38–42].
Application of a repetitive vascular occlusion stimulus
(RVOS) shows promise as a mitigating intervention. Re-
peated inflation/deflation of a blood pressure cuff around
a limb to above arterial pressure (~ 200mmHg) elicits
brief bouts (~ 5min) of limb ischaemia/reperfusion [43].
In healthy subjects, RVOS can improve exercise perform-
ance [44–47], whilst vascular occlusion during low-inten-
sity exercise (blood flow restriction exercise) can enhance
hypertrophic and strength responses in skeletal muscle
[48] of healthy controls [49–52], athletes [53] and the eld-
erly [54–60], and seems to improve physical function and
health-related quality of life in patients with inflammatory
muscle disease [61–63]. Moreover, RVOS may mitigate
against atrophy induced by immobilisation and unloading:
patients recovering from ligament reconstruction sur-
gery who received two sessions of RVOS (five cycles of
vascular occlusion for 5 min and release for 3 min) to
the proximal thigh daily for > 10 days after surgery had
50% less disuse knee extensor muscles mass loss [43].
Similarly, in healthy volunteers with experimentally
induced limb immobilisation, RVOS alone or in com-
bination with exercise preserved muscle strength and
mass [64, 65].
The mechanism by which RVOS prevents muscle atro-
phy remains unclear. Application of RVOS enhanced a
murine mTOR signalling pathway involved in protein
synthesis [66], whilst increased skeletal muscle oxidative
capacity is also implicated [67–70].
In addition to impacts on muscle mass, RVOS
improves local and systemic endothelial function and
microcirculation in healthy controls [71, 72], perhaps
through increases in plasma concentration of vascular
endothelial growth factor (VEGF) and endothelial pro-
genitor cells [73]. However, it is unknown whether
RVOS can prevent or offset macrovascular and micro-
vascular dysfunction observed in bed-rest/ immobilised
individuals [74–76] and critically ill patients [77–79].
Of note, such benefits are seen locally (i.e. in the
muscle distal to the occlusion), but also remotely—in tis-
sue distant from the site of occlusion (so-called ‘remote
preconditioning’). RVOS provides protection against
myocardial and renal tissue ischaemic injury at the time
of vascular intervention or cardiac surgery [80–85].
Unilateral daily arm RVOS over a week improves bi-
lateral vascular function [71], while a longer (300 con-
secutive days), more frequent (twice daily), protocol
improves cerebral perfusion and reduces recurrent
strokes by 30% in patients with intracranial arterial ste-
nosis [86]. The mechanism of such remote benefit has
yet to be described [87].
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Given its remote effects, application of RVOS to a sin-
gle limb could potentially prevent muscle wasting and
vascular dysfunction at both local and remote sites in
critically ill patients, thus mitigating against the develop-
ment of ICU-AW. Evidence suggests that this approach
would be safe, with no reports of elevation of muscle
damage markers, such as creatinine kinase and myoglo-
bin, and oxidative stress markers, such as lipid peroxide,
during blood flow restriction exercise [50, 52, 88, 89].
Moreover, RVOS pre or post exercise seems to be pro-
tective against exercise-induced muscle damage [90, 91].
Amongst 12,642 recipients (including healthy subjects,
older subjects and individuals with clinical conditions),
attributable serious side effects were few: venous
thrombus (0.055%), pulmonary embolism (0.008%) and
rhabdomyolysis (0.008%) [92]. No negative impact on
haemodynamic, haemostatic and inflammatory re-
sponses has been observed in healthy young, older and
clinical populations [61, 93–95]. In addition to being
safe, RVOS also appears well tolerated, with a pain score
of 3.6 ± 3.4 (mean ± SD) out of 10 during application to
the lower limb in patients with aneurysmal subarachnoid
haemorrhage [96].
We thus wish to determine whether the application of
RVOS might help maintain muscle mass and improve
vascular function in ICU patients. We here describe a
trial designed to assess the feasibility of performing such
an appropriately-powered study.
Methods
Primary objectives
The primary objective of the trial is to determine
whether it is safe and tolerable to apply RVOS to a pro-
ximal lower limb of ICU patients.
Secondary objectives
Our secondary objectives are to determine the feasibility
of screening; obtaining consent and recruiting; randomis-
ing; retaining patients; delivering the trial intervention;
performing outcome assessments and collecting data;
assessing acceptability for patients, personal consultees
(next of kin) and staff; and to determine outcome data
characteristics to design a future larger trial.
In addition, we will explore any impacts on measures of
muscle mass, quality and function (strength and physical
function measures); vascular function; blood and urine
biomarkers of muscle metabolism; vascular function;
inflammation and DNA damage/repair mechanisms; and
clinical outcomes to inform powering of any future
prospective trial.
Study design
ROSProx is a partially blinded interventional feasibility trial
with randomisation. Eligible patients will be randomised to
an intervention arm or a control arm. Patient randomised
to the control arm will receive standard care, while inter-
vention patients will receive RVOS treatment in addition to
all other standard care. The study protocol has been de-
veloped in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guide-
lines (see Additional file 1 for the SPIRIT checklist). The
study flow diagram is shown in Fig. 1.
Study setting
The study will take place within the ICUs of two hospi-
tals in England: Royal Surrey County Hospital NHS
Trust (RSCH); and Ashford and St Peter’s Hospital
(ASPH) NHS Trust.
Sample size rationale
A total of 30 participants is recommended for pilot and
feasibility trials [97]. To allow for balance in the stratifi-
cation factors (gender and study site), a sample size of
32 participants was chosen, which will allow us to esti-
mate a failure to deliver RVOS in the intervention arm
of 30% to within a 95% confidence interval of ± 15.9%.
Based on an anticipated average rate of recruitment of
6 patients/month, 50% screening failure due to week-
ends, 20% decline of consent and 30% death before trial
completion, we aim to recruit 1.6 patients per site per
month. Recruiting from two sites, one starting 2 months
after the other, is expected to yield 47 patients over 16
months. Recruitment will continue until 32 ICU survi-
vors have been studied (16 patients in each group).
Study population
Patients that meet the eligibility criteria (Table 1) will be
recruited from each participating ICU over a 16-month
period.
Recruitment and randomisation process
All sequential ICU admissions will be screened for eligi-
bility. Eligible patients with mental capacity for informed
consent will be approached, the risks and benefits of
participation explained and written informed consent
will be obtained before enrolment by the investigator
physician. However, we envision that the majority of eli-
gible patients will be receiving invasive mechanical ven-
tilation and requiring sedation, and thus lacking capacity
to consent. In this instance, declaration of agreement
will be sought from the patient’s ‘Personal Consultee’
who may be a representative, partner or close friend.
Once the participant recovers and is capable of under-
standing the details of the trial, they will be approached
to provide their informed consent retrospectively. If the
patient chooses to withdraw from the trial, they will be
given the choice of having their existing data and
samples destroyed or excluded from final analysis.
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Upon informed consent or declaration of agreement,
eligible patients will be randomised to either the inter-
vention arm or the control arm in a 1:1 ratio. Separate
randomisation lists have been prepared for each site by
an independent statistician and uploaded to the study
electronic data capture system PROMASYS (Surrey
Clinical Trials Unit). In addition, the randomisation list
and corresponding envelopes containing randomisation
assignments will be stored in the trial file. Randomisa-
tion, outcome measure assessments and RVOS interven-
tion will be performed by a research assistant unblinded
to patient allocation.
Study protocol
Figure 2 illustrates the schedule of study procedures and
outcome measure assessments. Briefly, within 24 h of
enrolment and randomisation, baseline assessments will
be completed. These will include ultrasound assessment
of muscle and arterial vascular function; blood and urine
sample collection and physical function assessment
using the ICU mobility score; recording of clinical char-
acteristics such as medical history, diagnosis and severity
of illness (assessed using the Sequential Organ Failure
Assessment (SOFA) score); documentation of physical
function (assessed using the Katz Index of Independence
in Activities of Daily Living score) and nutritional status
(assessed using the Malnutrition Screening Tool) prior
to illness.
If the participant is randomised to the intervention,
one RVOS session will be carried out after baseline
assessment on day 1. Arterial blood samples will be
collected 3 and 24 h after RVOS and at the same time
points after baseline assessments in control participants.
From day 2, intervention participants will receive two
RVOS sessions per day until day 10 of enrolment or
until ICU discharge if this occurs before day 10.
Fig. 1 Study flow diagram. ICU intensive care unit, SOFA Sequential Organ Failure Assessment
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Outcome measure assessments of muscle mass and
quality, arterial function, muscle strength, physical func-
tion, and blood and urine biomarkers will be repeated on
days 6 and 11 of study enrolment. Clinical data including
blood results, nutritional and organ support, severity of ill-
ness, fluid balance, physiotherapy interventions and spe-
cific drug treatment (neuromuscular blocking drugs,
corticosteroids, statins and propofol) will be recorded
daily from days 1 to 11 of enrolment. At ICU and hospital
discharge, physical function and muscle strength assess-
ments will be repeated. In addition, at hospital discharge,
an acceptability interview will be conducted with the
participant and personal consultee, and blood and urine
samples collected. Study participation will end upon com-
pletion (by telephone) of the SF-12 health questionnaire 3
months after hospital discharge.
Repetitive vascular occlusion stimulus (RVOS) intervention
Participants in the intervention arm will receive one
session of RVOS treatment on day 1 and two sessions
per day, at least 4 h apart, from day 2 to 10 of study
enrolment or until ICU discharge if this occurs before
day 10. For safety, the intervention leg will be examined
daily before the first RVOS session for deep vein throm-
bosis (DVT) from the common femoral to popliteal vein
using ultrasound (CX50 Philips Ultrasound with L12–3
linear array transducer). If DVT is suspected, RVOS or
arterial assessment will not be performed and the
clinical team will be notified immediately.
During the RVOS session, the participant will lie su-
pine in a semi-recumbent position with the lower limbs
extended. A pressure cuff (SC12LTM segmental pressure
cuff; Hokanson, Bellvue, WA, USA) will be applied
around the proximal right thigh with a bandage wrapped
underneath to avoid skin irritation and bruising. Each
RVOS session will last for 40 min and will include four
cycles of 5 min cuff inflation to 50mmHg above the
average systolic blood pressure to completely occlude
arterial flow distally to the limb [98], followed by 5 min
of complete deflation (0 mmHg) (Fig. 3). Pressure in the
pneumatic cuff will be controlled by an inflator and air
source device (E20 Rapid Cuff Inflator and AG101 Cuff
Inflator Air Source; Hokanson). Maximum cuff pressure
will be 200 mmHg.
Vital signs such as blood pressure, heart rate and the
saturation of peripheral arterial blood with oxygen will be
monitored before and during RVOS, and the session will
be terminated if the defined criteria are met (Table 2).
A clinical bedside nurse will be present throughout the
RVOS session and will monitor facial expression, limb
movement and ventilation compliance for any sign of
distress in the sedated participants. In the event that the
patient experiences significant discomfort, the cuff pres-
sure will be lowered to a pressure that is tolerated by the
participant, and such adjustments will be recorded. If
conscious, tolerability of the intervention will be eva-
luated by asking the participant to rate the pain of the
procedure on a visual analogue scale (VAS). After each
session, the intervention leg will be examined for signs
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Age≥ 18 years
2. Patient admitted to the ICU within the past 48 h
3. Personal consultee provides declaration of agreement
for patient enrolment, retrospective patient consent
4. Non-invasive ventilation (CPAP) or invasive mechanical
ventilation
5. At least two other organ failures as defined by scoring
≥ 1 points on two of the SOFA score domains
6. Likely to remain in the ICU for at least 4 days
1. Profound cardiovascular instability—infused vasopressors ≥ 0.5 μg/kg/min
of norepinephrine; or in opinion of senior attending doctor
2. Profound coagulopathy (prothrombin time > 2.5 times normal, APTT > 2 times
normal or platelet count ≤ 50), bleeding diathesis or on intravenous heparin
infusion APTR ≥ 2
3. Neuromuscular condition—any previous or concurrent neurological condition
or muscle disease
4. History of peripheral arterial vascular disease—any previous surgery or
interventional procedure for peripheral arterial insufficiency; or any reason to
clinically suspect arterial insufficiency of the leg, such as collateral history of
claudication or examination findings of absent peripheral pulses
5. Prior amputation of a lower limb
6. Thigh circumference > 77 cm (technical limitations)
7. Unlikely to survive the ICU
8. Disseminated malignancy
9. Pregnancy
10. Previous, or current, deep vein thrombosis and/or pulmonary embolism
11. Positioned prone
12. Contraindication to pharmacological venous thromboembolism prophylaxis
13. Pre-existing significant cognitive impairment
14. Enrolled in a conflicting interventional trial
15. Lack of ability to communicate in verbal and written English
16. Patient hospitalised > 48 h prior to ICU admission
17. Frail skin, skin condition or soft tissue infection or other reason that prevents
experimental use of upper limb
APTR activated partial thromboplastin time ratio, APTT activated partial thromboplastin time, CPAP continuous positive airway pressure, ICU intensive care unit,
SOFA Sequential Organ Failure Assessment
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Fig. 2 Schedule of study procedures and outcome measure assessments. DVT deep vein thrombosis, EDTA ethylenediamine tetraacetic acid, ICU
intensive care unit, RVOS repetitive vascular occlusion stimulus, SF-12 12-Item Short Form Health Questionnaire
Fig. 3 Protocol for repetitive vascular occlusive stimulus (RVOS). Each session of RVOS includes four repetitions of 5-min inflation of pneumatic
cuff to 50mmHg supra-systolic blood pressure (SBP) followed by 5 min of complete (0 mmHg) cuff deflation
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of arterial insufficiency or tissue injury. In addition,
serum creatinine kinase levels will be monitored daily as
an indicator of muscle damage.
Primary outcome measures
Safety
The number of serious adverse events (SAEs; DVT, pul-
monary embolism and elevated serum creatine kinase
concentration (creatine kinase > 3800 IU/L)) will be
compared between the control and intervention groups.
Tolerability
The VAS pain score will be used to assess the tolerability
of RVOS.
Secondary outcome measures
Feasibility
Table 3 presents the pre-specified feasibility criteria that
will be assessed.
Acceptability
A semi-structured interview conducted with the partici-
pant, personal consultee and clinical staff will be used to
determine the acceptability of trial experience and RVOS
intervention. Questions will relate to key trial para-
meters such as experience of recruitment and rando-
misation and participant/staff burden (see Additional file 2
for acceptability questions).
Muscle mass and quality
To assess muscle mass, the rectus femoris (RF) muscle of
both legs (in intervention participants) and only the right
leg (control participants) will be imaged using B-mode
ultrasound as previously described [21, 99] at baseline and
on days 6 and 11 of study enrolment. Briefly, the partici-
pant will lie in a semi-recumbent position and the RF
muscle will be scanned in the longitudinal plane on the
anterior aspect of the thigh, two-thirds of the distance
from the anterior superior iliac spine to the superior
patella border. RF ultrasound images will be analysed
using ImageJ software (NIH, Bethesda, MD, USA) by
blinded investigators. Muscle mass will be quantified
by assessing the RFCSA, and echogenicity will be
measured to evaluate the changes in muscle quality
as reported previously [100, 101]. Change over time
in these measures will be compared between interven-
tion and control participants, and changes in the
treated leg and the untreated leg compared in those
receiving the RVOS intervention.
Table 2 Termination criteria for repetitive vascular occlusion
stimulus (RVOS) session
1. Heart rate < 40 bpm or > 180 bpm
2. Systolic blood pressure < 80 mmHg or > 200mmHg
3. Mean arterial blood pressure < 60 mmHg or > 120mmHg
4. Peripheral capillary oxygen saturation (SpO2) < 88%
5. Pain score > 8/10 on visual analogue scale and unwillingness to
proceed with RVOS intervention
6. Objective signs of tissue injury felt due to cuff inflation
Table 3 Feasibility criteria of the study
Trial process Outcome measure Feasibility criteria
Screening Percentage of potentially eligible
patients being missed
< 55% of potentially eligible patients being missed
Consent Percentage of personal consultee/participants
agreeing to enrolment
> 75% of personal consultees/participants agreeing
to enrolment
Recruitment rate Number of patients recruited Recruit 30 patients within 16 months
Randomisation Demographic and severity of illness in
the intervention and control arms
Balanced demographic and severity of illness in
intervention and control arm participants
Delivery of intervention Percentage of RVOS sessions performed
out of the total possible sessions
80% of the scheduled RVOS sessions performed
Retention rate Percentage of patients that remain on the
ICU for the full 10 days of study enrolment
> 50% of enrolled patients remain on the ICU for the
full 10 days of study enrolment
Outcome measure
assessments
Percentage of outcome measure assessments
performed within 24 h of the scheduled time
Percentage of quality-of-life questionnaires
completed at 90-day follow-up
100% of RFCSA ultrasound measurements performed
within 24 h of the scheduled time
> 75% of vascular, strength and functional capacity
measures performed within 24 h of the scheduled time
> 75% of surviving patients complete the quality-of-life
questionnaires
at 90-day follow-up
Electronic case report
form data collection
Percentage of missing outcome and clinical
data
< 10% missing outcome data including ICU and hospital
length of stay and survival
< 10% missing clinical data obtained from clinical medical
notes and electronic patient records, such as severity of illness
scores and requirement for organ supportive therapies
ICU intensive care unit, RFCSA rectus femoris cross sectional area, RVOS repetitive vascular occlusion stimulus
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Arterial vascular measures
Arterial vascular function will be assessed at the same
time points as muscle evaluation, using techniques previ-
ously described [102]. The diameter and blood flow
velocity of the right superficial femoral artery at rest and
immediately following 5min of ischaemia will be
measured using B-mode and pulse Doppler ultrasound
imaging, respectively. Ischaemia will be induced by appli-
cation of a pneumatic cuff to the right thigh and inflation
to 200 mmHg cuff pressure. Blinded investigators will
analyse the diameter and blood flow velocity using
the commercially available software Brachial Analyzer
(Vascular Research Tools 5; Medical Imaging Appli-
cations, LLC, Coralville, IA, USA) to assess flow-me-
diated dilation (FMD) and reactive hyperaemic
response, surrogate markers of vascular health. The
reactive hyperaemic response is a transient increase in
blood flow in response to ischaemic stimulus, and a
marker of vasodilator capacity of resistance vessels.
FMD assesses endothelial-dependent vasodilation of
the conduit artery in response to increased blood flow
and internal wall shear stress. The resting SFA dia-
meter and blood velocity, reactive hyperaemic response
and FMD will be compared between intervention and
control participants at each time point.
Muscle strength
On days 6 and 11 and at ICU and hospital discharge, the
grip strength of the dominant hand will be assessed
using a handgrip dynamometer (Takei Scientific Instru-
ments Co. Ltd, Niigata City, Japan) and manual muscle
strength evaluation of the bilateral six upper and lower
limb muscle groups (shoulder abductors, elbow flexors,
wrist extensors, hip flexors, knee extensors and foot dor-
siflexors) performed using the Medical Research Council
Sum Score (MRC-SS) [103]. Strength assessments will
only be performed if the participant is sufficiently alert
and free from delirium.
Physical function
Mobility will be assessed in the ICU on days 1, 6 and 11
of study enrolment (or at ICU discharge, whichever is
earlier) and at hospital discharge, using the ICU Mobility
Scale, a validated measure with excellent clinometric
properties [104, 105]. In addition, functional assessment
(‘timed up and go’ and ‘sit to stand’) will be performed at
hospital discharge. ‘Timed up and go’ will involve meas-
uring the time taken to stand up from a standard chair,
walk a 3-m distance at normal pace and return to the
chair; for ‘sit to stand’, the number of times that the par-
ticipant is able to completely stand upright from a stand-
ard chair and sit back down fully within 30 s will be
assessed. Due to the study population being frail, use of
aids will be permitted and documented.
Clinical outcomes
Clinical outcomes between participants in the interven-
tion and control arms will be compared: incidence and
duration of delirium; incidence, duration and severity of
acute kidney injury (assessed using the AKIN classifica-
tion) [106]; duration of specific organ support (mechan-
ical ventilation, renal replacement therapy, mechanical
or pharmacological cardiovascular support); days alive
and without a ventilator in the first 28 days of hospital
stay; length of ICU and hospital stay; and hospital and 3-
month mortality.
Laboratory assessment
A 10-ml urine sample (collected from an indwelling
urinary catheter) and 1 × 10 ml EDTA, 3 × 4ml EDTA,
1 × 4ml serum, 1 × 3ml Tempus™ RNA blood tube
samples will be collected on days 1, 6 and 11 of study
enrolment from indwelling arterial cannulae, and via
venepuncture at hospital discharge. In addition, 1 × 4ml
EDTA blood samples will be taken at 3 and 24 h after
the first RVOS session in patients randomised to the
intervention arm and similarly at 3 and 24 h after base-
line assessment in control participants. Plasma and
serum will be separated from the EDTA and serum
tubes, and the urine sample and Tempus™ blood RNA
will be stored at − 80 °C. The, 1 × 10 ml EDTA will be
processed to isolate peripheral blood mononuclear cells
(PBMCs) using the Optiprep™ protocol [107], which will
be stored at − 80 °C until analysis.
Samples will be stored in accordance with the Human
Tissue Act (2004) beyond the end of the trial to allow for
various laboratory analyses to evaluate mechanisms be-
hind the effect of RVOS. Biomarkers that will be analysed
are presented in Table 4. Further biomarkers may be
studied to evaluate mechanisms of effect as scientific
evidence dictates.
Statistical analysis
The statistical analysis addresses the objectives of dem-
onstrating the safety and tolerability of applying RVOS
to the lower proximal limb of ICU patients, and asses-
sing the feasibility of undertaking a larger-scale study to
demonstrate efficacy. As a feasibility trial, the statistical
analysis will primarily be exploratory in nature, and thus
hypothesis generating rather than confirmatory.
The primary objective of safety will be evaluated based
on the frequencies and percentages of adverse events
categorised by severity, group and site. The tolerability
will be evaluated by assessing VAS pain scores of the
intervention arm at each time point in terms of means
and standard deviations.
The main feasibility outcome of recruitment will be
evaluated as the percentage of randomised participants
out of total eligible patients. The number of participants
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randomised as a percentage of targeted recruitment will
also be computed. If data are available, the average num-
ber of research assistants’ hours spent on recruiting one
participant will also be computed. Retention will be
evaluated as the proportion of participants remaining at
each time point compared to the number recruited in
each arm.
Descriptive statistics will be used to summarise all
response variables by site, time point and treatment
group. Means and standard deviations will be computed
for continuous outcomes and frequencies and percent-
ages will be computed for categorical/dichotomous out-
comes. The relationship with potential confounding
factors—such as site, demographic data, delirium during
ICU stay, severity of illness, length of ICU stay, sepsis
(defined using SOFA score), and use of drug treatment
(such as corticosteroids, neuromuscular blocking drugs,
statins and propofol)—will be explored.
The following inferential statistics will be performed
strictly for the purpose of identifying the directions and
magnitudes of effects rather than to evaluate the statis-
tical significance of the results due to inadequacy of stat-
istical power.
Outcome measures recorded at a time point (such as
‘timed up and go’ and ‘sit to stand’ assessment) and clin-
ical outcomes (such as duration of mechanical venti-
lation and length of ICU and hospital stay) will be
compared between the two arms using an independent-
sample t test.
Repeated outcome measures such as the RFCSA and
echogenicity, superficial femoral artery measures (resting
diameter and blood flow, FMD and reactive hyperaemic
response), ICU mobility score, MRC-SS and handgrip
strength data will be analysed separately as the response
variable in a general linear mixed model using SAS PROC
MIXED, with group (the dichotomy of standard care or
RVOS), site, baseline measure, time and group × time
interaction as fixed effects and subject as random effects.
Appropriately selected covariates will be included in the
model as fixed effects to adjust for the variability caused
by these covariates.
All statistical analyses will be performed by the Trial
Statistician at Surrey Clinical Trials Unit (CTU) according
to a pre-specified Statistical Analysis Plan, which will be
finalised and signed off before the database lock.
Data collection and monitoring
All study data will be collected in compliance with the
principles of Good Clinical Practice (GCP) and with the
Data Protection Act. Patients’ medical notes will be used
as source documents for clinical data, while data related
to the RVOS intervention (e.g. time of session, cuff pres-
sure, VAS score) and outcome measure assessments will
be recorded in a paper workbook before transcribing to
a secure web-based electronic data capture system
(Promasys) provided by Surrey CTU. The Surrey CTU
data management team and sponsor (RSCH) will jointly
oversee the administration of study documentation to
ensure that study data are authentic, accurate and
complete. The sponsor’s Quality and Assurance Officer
will conduct monitoring visits to review the source
documentation and electronic case report forms (eCRF)
and to evaluate them for accuracy, completeness and
compliance with the approved protocol, applicable
regulations and GCP standards. The frequency of the
monitoring visits will depend on the findings of the first
patient-monitoring visit at each site.
Participants’ anonymity will be maintained at all times,
and study workbooks and other documents will only be
labelled with a non-identifiable study participant num-
ber. Paper documents that identify participants (such as
consent forms) will be stored in a separate folder in a
locked office of the secured department site and main-
tained by investigators in strict confidence. At the end of
the trial, any non-essential confidential documents will
be destroyed and essential documents will be kept
securely for at least 10 years after study completion.
Trial monitoring groups
Day-to-day management of the trial will be the responsi-
bility of the Trial Management Group (TMG), members
of which will include the Chief Investigator and co-investi-
gators, the research assistant, the CTU Trial Statistician
and Data Manager, and the sponsor’s Quality and Assu-
rance Officer. The group will monitor all aspects of the
conduct and progress of the trial including recruitment
figures, data quality and protocol adherence. In addition,
experts in the study research field (consultant intensivists,
Chief and Principle Investigators, sponsor and CTU re-
presentatives) and patient and public involvement (PPI)
members have been appointed as members of a Trial
Table 4 Laboratory analysis
Sample Biomarkers
Plasma and serum Muscle anabolic marker insulin-like growth
factor 1
Muscle catabolic marker Myostatin
Inflammatory cytokines interleukin (IL)-6,
IL-10, tumour necrosis factor α,
granulocyte–macrophage colony-stimulating
factor, macrophage inflammatory protein 1,
transforming growth factor β1
Angiogenic factors vascular endothelial growth
factor, hypoxia inducible factor 1α
Tempus RNA tube MicroRNAs linked with muscle atrophy such
as miR-29b, miR-542-5p and miR-424-5p [108]
Peripheral blood
mononuclear cells
DNA damage/repair enzymes GAD45a and
APE-1
Urine Oxidative stress-derived DNA damage
marker 8-hydroxy deoxyguanosine
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Steering Committee (TSC). The TSC will be responsible
for overseeing conduct of the trial and will convene every
6 months, will review trial progress, recruitment rates,
safety data (reviewed blinded to treatment allocation) and
ethical issues, and will make recommendations for proto-
col modifications. In the case of major safety concerns,
the TSC will be able to request unblinded review of the
safety data.
In order to safeguard the interests of trial participants,
an independent Trial Safety Group (TSG) has been
appointed and will be updated with safety data after
every five patients recruited or in the event of an SAE
occurring. The TSG will be responsible for monitoring
any evidence for treatment harm, informing the TSC of
any safety concerns and advising with regard to protocol
modifications suggested by investigators or sponsors.
Four previous ICU-AW sufferers and their carers who
constitute our Project Advisory Group (PAG) were in-
volved in defining the research questions and in aiding
development of a patient-friendly study design. The
PAG has reviewed and advised on language and content
of participant-related study documents. Some members
are also TSC members and will be involved in the deliv-
ery and management of the trial. At the end of the study,
they will also assist in writing a letter thanking partici-
pants for their involvement and lay summary of findings.
Serious adverse events
Safety reporting will be performed in accordance with
HRA guidelines for non-CTIMP research (not involving
investigational medicinal products or medical devices)
with adherence to GCP standards. Untoward medical
occurrences are expected in critically ill patients and
their monitoring and treatment is considered standard
care. As a result, only serious adverse events (SAEs) will
be reported. These are defined as any untoward occur-
rence that results in death; is life-threatening; requires
hospitalisation or prolongs existing hospitalisation; or
results in persistent or significant disability/incapacity;
or any other important medical event that required
intervention to prevent the outcomes already listed
based upon appropriate judgement by the investigators.
SAEs will be recorded from when participant consent is
obtained to 3-month follow-up after hospital discharge.
SAEs possibly, probably and definitely related to the study,
such as DVT, pulmonary embolism and elevated creatine
kinase (creatine kinase > 3800 IU/L), will be recorded. For
all SAEs, the following data will be recorded in the eCRF
and patient notes: description; date and time of occur-
rence; severity; relationship of SAE to study procedure
(determined by the investigator physician); treatment re-
quired; and action taken with research procedure. The
completed SAE form, signed by the reporting investigator
and Principle Investigator of the site, will be submitted to
the sponsor within 24 h of becoming aware of the event
and all SAEs will be followed-up until resolved. If unex-
pected serious related event occurs, the Chief Investigator
will notify Principle Investigators at local sites and the
research ethics committee within 15 days of the event.
In the case of unanticipated concerns of safety to study
participants or availability of new data arising from
clinical or preclinical studies with this intervention, the
study will be paused during review of newly available
data prior to a final decision for continuation or termi-
nation of the study. If, in the opinion of the Chief
Investigator, the clinical events indicate that it is not
justifiable to continue the trial, the TSC will terminate
the trial following consultation with the sponsor.
Indemnity
The Royal Surrey County Hospital Foundation Trust, as
the trial sponsor, holds professional liability insurance to
meet the potential legal liability of the sponsor and em-
ployees for harm to participants arising from the design
and management of the research.
Indemnity to meet the potential legal liability of the in-
vestigators/collaborators for the harm of participants
arising from the conduct of the research is provided by
the NHS Indemnity scheme or through professional
indemnity.
Dissemination of results
Study results will be published in peer-reviewed journals
and presented at international/national surgical, anaes-
thetic and perioperative medicine conferences.
In addition, a lay summary of findings will be dissemi-
nated to study participants.
Discussion
This study will be the first to assess the safety, tolerabil-
ity, feasibility and acceptability of RVOS in ICU patients.
The effect of RVOS on muscle mass atrophy and weak-
ness, and on arterial dysfunction observed in ICU
patients, will also be explored.
Thirty-two ventilated critically ill patients with at least
two other organ failures will be recruited to the study.
Multiple organ failure patients were chosen as the study
population because these patients undergo more pro-
nounced muscle wasting (16% decrease in the RFCSA
compared to 3% in single organ failure patients within 7
days of ICU admission) [21].
RVOS will be performed using equipment conventionally
and safely used for vascular disease diagnostics and rou-
tinely used during vascular and orthopaedic operations.
Control participants will receive standard care and no sham
treatment (repeated cuff inflation at lower pressure) so as
to avoid any detrimental impacts of isolated venous occlu-
sion. Participants will thus not be blinded in the study.
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However, this is unlikely to introduce bias to the objective
measures as muscle and arterial ultrasound images will be
anonymised and analysed blinded to subject identity, study
time points and group allocation.
The tolerability of RVOS cannot be assessed when par-
ticipants are ventilated and sedated. Even when partici-
pants are extubated and off sedation, delirium (an acute
brain dysfunction) is common in critically ill patients
and can influence the VAS score. CAM-ICU assessment
will be performed and the mental state of the participant
during the RVOS session will be recorded to observe
any effects of delirium on the VAS score.
Ultrasound assessments of muscle mass and quality
and arterial function can be performed when partici-
pants are sedated; however, muscle strength and physical
function measures are volitional assessments and require
the participant’s full attention and cooperation. There-
fore, sedation, lack of willingness to participate or lack
of mental capacity due to delirium can prevent these
outcome assessments. These measures will therefore
only be performed when the participant is off sedation
and CAM-ICU negative; this could lead to the time
points when the strength and physical function assess-
ments are performed varying between participants.
Our study population has a high risk of hospital death
and post-discharge mortality. This means that partici-
pants could be lost due to death before completion of
the study, with previous reports of 30% mortality in a
study with similar inclusion and exclusion criteria [109].
We will recruit until we have 32 participants that survive
the ICU stay, recognising that subsequent deaths after
ICU discharge may reduce the data available at hospital
discharge and at 3-month follow-up.
We expect repeated inflation and deflation of the
pneumatic cuff during the RVOS to cause minor fluctua-
tions in heat rate and blood pressure. As a result, pa-
tients with profound cardiovascular instability (defined
by infused vasopressors ≥ 0.5 μg/kg/min of norepineph-
rine or by opinion of the senior attending physician) will
not be studied. Moreover, during the RVOS session,
haemodynamic parameters will be monitored closely.
Critically ill patients have a 10% incidence rate of DVT
[110], whilst an incidence of 0.055% is reported in others
who have received blood flow restriction exercise [92].
We will thus exclude patients with a history of DVT and
pulmonary embolism (PE) as well as patients who have
contraindication to pharmacological venous thrombo-
embolism prophylaxis. Apart from an incidence of minor
events such as skin petechiae (4.4%) and subcutaneous
bruising (13.1%), no major bleeding risk of RVOS has
been reported in the literature [92, 111]. However, as a
safety measure, patients with profound coagulopathy
(defined by > 2.5 times normal prothrombin time, > 2
times normal APTT, platelet count ≤ 50 or on IV
heparin infusion APTR ≥ 2) will not be recruited or
studied if this occurs.
If our pilot study shows that RVOS is safe, feasible and
acceptable to apply to ICU patients, an appropriately-
powered randomised controlled trial will be designed to
assess any potential benefit of this procedure.
Trial status
The study was opened to recruitment at the RSCH site in
October 2017 and at the ASPH site in January 2018, and
the first participant was recruited in January 2018. Study
recruitment was completed in Feburary 2019.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist: recommended items to
address in a clinical trial protocol and related documents (DOC 137 kb)
Additional file 2: Acceptability questions (DOCX 14 kb)
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